KNSA (Kiniksa Pharmaceuticals International) ROE % Adjusted to Book Value : -2.48% (As of Dec. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Kiniksa Pharmaceuticals International ROE % Adjusted to Book Value?

Kiniksa Pharmaceuticals International's ROE % for the quarter that ended in Dec. 2024 was -8.12%. Kiniksa Pharmaceuticals International's PB Ratio for the quarter that ended in Dec. 2024 was 3.27. Kiniksa Pharmaceuticals International's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2024 was -2.48%.

Kiniksa Pharmaceuticals International ROE % Adjusted to Book Value Historical Data

The historical data trend for Kiniksa Pharmaceuticals International's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kiniksa Pharmaceuticals International ROE % Adjusted to Book Value Chart

Kiniksa Pharmaceuticals International Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

ROE % Adjusted to Book Value

Get a 7-Day Free Trial

-15.56

-14.48

23.90

1.20

-3.01

Kiniksa Pharmaceuticals International Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
ROE % Adjusted to Book Value	Get a 7-Day Free Trial															8.48	-5.04	-1.18	-2.82	-2.48

Competitive Comparison of Kiniksa Pharmaceuticals International's ROE % Adjusted to Book Value

For the Drug Manufacturers - Specialty & Generic subindustry, Kiniksa Pharmaceuticals International's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Kiniksa Pharmaceuticals International's ROE % Adjusted to Book Value Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Kiniksa Pharmaceuticals International's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Kiniksa Pharmaceuticals International's ROE % Adjusted to Book Value falls into.

Save Embed

Kiniksa Pharmaceuticals International ROE % Adjusted to Book Value Calculation

Kiniksa Pharmaceuticals International's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2024 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-9.85%	/	3.27
	=	-3.01%

Kiniksa Pharmaceuticals International's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2024 is calculated as

ROE % Adjusted to Book Value	=	ROE %	/	PB Ratio
	=	-8.12%	/	3.27
	=	-2.48%

Kiniksa Pharmaceuticals International ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of Kiniksa Pharmaceuticals International's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Kiniksa Pharmaceuticals International Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Kiniksa Pharmaceuticals International PLC (NAS:KNSA) » Definitions » ROE % Adjusted to Book Value

Comparable Companies

Traded in Other Exchanges

N/A

Address

23 Old Bond Street, Floor 3, London, GBR, W1S 4PZ

Website

https://www.kiniksa.com

Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.

Executives

Mark Ragosa	officer: Interim CFO	C/O KINIKSA PHARMACEUTICALS CORP., 100 HAYDEN AVENUE, LEXINGTON MA 02421
Michael R Megna	officer: Chief Accounting Officer	1050 HINGHAM STREET, ROCKLAND MA 02370
Eben Tessari	officer: Chief Business Officer	C/O KINIKSA PHARMACEUTICALS LTD., CLARENDON HOUSE, 2 CHURCH STREET, HAMILTON D0 HM11
Sanj K Patel	director, 10 percent owner, officer: Chairman & CEO	C/O KINIKSA PHARMACEUTICALS, LTD., CLARENDON HOUSE, 2 CHURCH STREET, HAMILTON D0 HM11
Ross Moat	officer: Group VP & Rilonacept GM	C/O KINIKSA PHARMACEUTICALS LTD., CLARENDON HOUSE, 2 CHURCH STREET, HAMILTON D0 HM11
John Paolini	officer: Chief Medical Officer	C/O KINIKSA PHARMACEUTICALS, LTD., CLARENDON HOUSE, 2 CHURCH STREET, HAMILTON D0 HM11
Barry D Quart	director	C/O INTRABIOTICS PHARMACEUTICALS INC, 1009 OAK HILL ROAD, SUITE 201, LAFAYETTE CA 94549
Felix Baker	director	BAKER BROS. ADVISORS LP, 860 WASHINGTON STREET 3RD FLOOR, NEW YORK NY 10014
Julian Baker	director	BAKER BROS. ADVISORS LP, 860 WASHINGTON STREET 3RD FLOOR, NEW YORK NY 10014
Baker Bros. Advisors Lp	director	860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Baker Brothers Life Sciences Lp	director	860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
L.p. 667,	director	860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Arian Pano	officer: Chief Clinical Dev. Officer	C/O KINIKSA PHARMACEUTICALS LTD., CLARENDON HOUSE, 2 CHURCH STREET, HAMILTON D0 HM11
Thomas W. Beetham	10 percent owner, officer: Chief Legal Officer	C/O KINIKSA PHARMACEUTICALS, LTD., CLARENDON HOUSE, 2 CHURCH STREET, HAMILTON D0 HM11
G Bradley Cole	director	301 PENOBSCOT DRIVE, REDWOOD CITY CA 94063